1-7 of 7
Jonathan S. Cebon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Open Access
Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View articletitled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Available to Purchase
Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View articletitled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

Free
Victoria J. Mar, Stephen Q. Wong, Jason Li, Richard A. Scolyer, Catriona McLean, Anthony T. Papenfuss, Richard W. Tothill, Hojabr Kakavand, Graham J. Mann, John F. Thompson, Andreas Behren, Jonathan S. Cebon, Rory Wolfe, John W. Kelly, Alexander Dobrovic, Grant A. McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4589–4598.
https://doi.org/10.1158/1078-0432.CCR-13-0398
Published: 02 September 2013
View articletitled, BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Open the PDF for BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage in another window
Includes: Supplementary data
Journal Articles

Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma

Free
Thomas John, Michael A. Black, Tumi T. Toro, Debbie Leader, Craig A. Gedye, Ian D. Davis, Parry J. Guilford, Jonathan S. Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5173–5180.
https://doi.org/10.1158/1078-0432.CCR-07-4170
Published: 12 August 2008
View articletitled, Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma
Open the PDF for Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma in another window
Includes: Supplementary data
Journal Articles

ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non–Small Cell Lung Cancer

Free
Thomas John, Otavia L. Caballero, Suzanne J. Svobodová, Alan Kong, Ramon Chua, Judy Browning, Sheila Fortunato, Siddhartha Deb, Melinda Hsu, Craig A. Gedye, Ian D. Davis, Nasser Altorki, Andrew J. Simpson, Yao-Tseng Chen, Marilyn Monk, Jonathan S. Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3291–3298.
https://doi.org/10.1158/1078-0432.CCR-07-1322
Published: 02 June 2008
View articletitled, ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non–Small Cell Lung Cancer
Open the PDF for ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Free
Andrew M. Scott, Fook-Thean Lee, Robert Jones, Wendie Hopkins, Duncan MacGregor, Jonathan S. Cebon, Anthony Hannah, Geoffrey Chong, Paul U, Anthony Papenfuss, Angela Rigopoulos, Susan Sturrock, Roger Murphy, Veronika Wirth, Carmel Murone, Fiona E. Smyth, Simon Knight, Sydney Welt, Gerd Ritter, Elizabeth Richards, Edouard C. Nice, Antony W. Burgess, Lloyd J. Old
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4810–4817.
https://doi.org/10.1158/1078-0432.CCR-04-2329
Published: 06 July 2005
View articletitled, A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake
Open the PDF for A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake in another window
Journal Articles

Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma

Free
Geoffrey Chong, Fook Thean Lee, Wendie Hopkins, Niall Tebbutt, Jonathan S. Cebon, Angela J. Mountain, Bridget Chappell, Anthony Papenfuss, Paul Schleyer, Paul U, Roger Murphy, Veronika Wirth, Fiona E. Smyth, Nicole Potasz, Aurora Poon, Ian D. Davis, Tim Saunder, Graeme J. O'Keefe, Antony W. Burgess, Eric W. Hoffman, Lloyd J. Old, Andrew M. Scott
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4818–4826.
https://doi.org/10.1158/1078-0432.CCR-04-2330
Published: 06 July 2005
View articletitled, Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
Open the PDF for Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma in another window